Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06900530 · ClinicalTrials.gov registry record

Evaluating Sleep Quality With Emerging Technologies

A clinical trial of Hypoxia and Obstructive Sleep Apnea (OSA), sponsored by Case Western Reserve University.

Completed
Registry status
52
Enrollment target
1
Study location

NCT06900530: Completed study of Hypoxia and Obstructive Sleep Apnea (OSA), sponsored by Case Western Reserve University.

NCT06900530 is a study of Hypoxia and Obstructive Sleep Apnea (OSA) that has completed, run by Case Western Reserve University. The registered enrollment target is 52 participants, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06900530, a study of Hypoxia and Obstructive Sleep Apnea (OSA), has completed, sponsored by Case Western Reserve University.

COMPLETED
Registry status
52 participants
Enrollment target
1
Study location

Study Summary

To investigate the sleep quality of the adult orthodontic patient population at the Case Western Reserve University School of Dental Medicine using the NOSE Questionnaire, STOP-BANG Questionnaire, SleepCycle app, and Belun Ring. The sample will consist of adult orthodontic patients who came seeking care at the Case Western Reserve University School of Dental Medicine's Orthodontic Department. Inclusion criteria include adult patients in active treatment in the Case Western Reserve University School of Dental Medicine's Orthodontics Department, age 20 or higher, willingness to give informed consent and participate in the study, possession of a smartphone, and ability to return the Belun Ring and complete the follow-up questionnaire. Exclusion criteria include age less than 20, current or history of taking blood pressure medication, pregnancy, hypovolemia, allergy to thermoplastic elastomers or polycarbonates, anemia, use of mandibular repositioning devices, or active palatal expansion. There were no existing publications similar to our study found in the current literature. So, the required sample size was estimated by the G Power formula for prevalence studies. The global prevalence of AHI 15 was used to estimate the required sample size for this study. The required sample size for 80% power and .05 precision came to 26 subjects.

Primary Outcome

The NOSE questionnaire is a validated tool that assesses nasal blockage. It provides an objective score that ranges from 0 to 100 with lower scores indicating less nasal blockage and higher scores indicating worse nasal blockage.

Study Locations (1)

Ohio

  • Case Western Reserve University Dental Clinic - Orthodontics - Cleveland

Trial Details

FieldValue
Enrollment Target 52 participants
Start Date 2024-02-10
Est. Completion 2025-12-15
Case Western Reserve University

141 total trials

What the finished NCT06900530 record still lists

NCT06900530 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 3,116-participant average among 39 other Hypoxia trials with a reported enrollment target (98% lower).

The record links to 4 conditions, with Hypoxia appearing as the primary indexed condition, and to 0 interventions.

NCT06900530 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT06900530 about?

NCT06900530 is a clinical study titled "Evaluating Sleep Quality With Emerging Technologies". To investigate the sleep quality of the adult orthodontic patient population at the Case Western Reserve University School of Dental Medicine using the NOSE Questionnaire, STOP-BANG Questionnaire, SleepCycle app, and Belun Ring. The sample will consist of adult orthodontic patients who came seeking...

What is the current status of trial NCT06900530?

This trial is currently completed. The enrollment target is 52 participants. The study started on 2024-02-10. Estimated completion is 2025-12-15.

What conditions does trial NCT06900530 study?

This clinical trial studies the following conditions: Hypoxia, Obstructive Sleep Apnea (OSA), Snoring, Sleep Disturbances.

Who is sponsoring clinical trial NCT06900530?

This trial is sponsored by Case Western Reserve University, which has 141 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06900530 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hypoxia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06900530's enrollment target sits among peer trials

52 16th of 39 higher than 24 of 39 other Hypoxia trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hypoxia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02630121 · 52 participants · Phase 4

    Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea

  • NCT03629171 · 52 participants · Phase 2

    Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia

  • NCT04128748 · 52 participants · Phase 1

    Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome

  • NCT04150497 · 52 participants · Phase 1

    Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06900530, the US trial registry maintained by the National Library of Medicine. NCT06900530 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.